Latest filings (excl ownership)
15-12B
Securities registration termination
12 Apr 21
EFFECT
Notice of effectiveness
6 Apr 21
EFFECT
Notice of effectiveness
6 Apr 21
S-8 POS
Registration of securities for employees (post-effective amendment)
1 Apr 21
S-8 POS
Registration of securities for employees (post-effective amendment)
1 Apr 21
POS AM
Prospectus update (post-effective amendment)
1 Apr 21
POS AM
Prospectus update (post-effective amendment)
1 Apr 21
8-K
Completion of Acquisition or Disposition of Assets
1 Apr 21
SC 14D9/A
Tender offer solicitation (amended)
1 Apr 21
SC TO-T/A
Third party tender offer statement (amended)
1 Apr 21
25-NSE
Exchange delisting
1 Apr 21
10-K/A
2020 FY
Annual report (amended)
31 Mar 21
SC TO-T/A
Third party tender offer statement (amended)
22 Mar 21
SC 14D9/A
Tender offer solicitation (amended)
22 Mar 21
S-8
Registration of securities for employees
12 Mar 21
10-K
2020 FY
Annual report
12 Mar 21
SC 14D9
Tender offer solicitation
4 Mar 21
SC TO-T
Third party tender offer statement
4 Mar 21
SC14D9C
Written communication relating to third party tender offer
26 Feb 21
SC14D9C
Written communication relating to third party tender offer
25 Feb 21
SC TO-C
Information about tender offer
25 Feb 21
8-K
Tender and Support Agreement
25 Feb 21
8-K
Pandion Therapeutics Announces Positive Top-Line Phase 1a Clinical Data Showing PT101 was Well-Tolerated and Selectively Expanded Regulatory T cells
4 Jan 21
8-K
Pandion Therapeutics Appoints Katina Dorton to its Board of Directors
3 Dec 20
10-Q
2020 Q3
Quarterly report
16 Nov 20
8-K
Pandion Therapeutics Reports Third Quarter 2020 Financial Results and Provides Business Update
16 Nov 20
10-Q
2020 Q2
Quarterly report
31 Aug 20
8-K
Pandion Reports Second Quarter 2020 Financial Results and Provides
31 Aug 20
8-K
Amendments to Articles of Incorporation or Bylaws
21 Jul 20
S-8
Registration of securities for employees
17 Jul 20
424B4
Prospectus supplement with pricing info
17 Jul 20
EFFECT
Notice of effectiveness
17 Jul 20
S-1MEF
Registration of additional securities for an S-1
16 Jul 20
CERT
Certification of approval for exchange listing
16 Jul 20
S-1/A
IPO registration (amended)
16 Jul 20
SEC STAFF
SEC staff action: Order
15 Jul 20
CORRESP
Correspondence with SEC
14 Jul 20
CORRESP
Correspondence with SEC
14 Jul 20
8-A12B
Registration of securities on exchange
13 Jul 20
S-1/A
IPO registration (amended)
13 Jul 20
Latest ownership filings
SC 13G/A
ORBIMED ADVISORS LLC
11 Feb 22
SC 13G/A
RA CAPITAL MANAGEMENT, L.P.
17 May 21
SC 13D/A
GLAXOSMITHKLINE PLC
8 Apr 21
SC 13D/A
AI Pan LLC
2 Apr 21
4
Joanne L. Viney
1 Apr 21
4
Vikas Goyal
1 Apr 21
4
Alan L Crane
1 Apr 21
4
Edward D. Freedman
1 Apr 21
4
GREGG BELOFF
1 Apr 21
4
Rahul Kakkar
1 Apr 21
4
Christopher Fuglesang
1 Apr 21
4
Daniel J. Becker
1 Apr 21
4
John Sundy
1 Apr 21
4
Nancy Stagliano
1 Apr 21
4
Katina Dorton
1 Apr 21
4
Donald Frail
1 Apr 21
4
Jill Carroll
1 Apr 21
4
Rizzuto Carlo
1 Apr 21
4
Eric D Larson
1 Apr 21
SC 13D
AI Pan LLC
4 Mar 21
SC 13D
Merck & Co., Inc.
4 Mar 21
3
Initial statement of insider ownership
4 Mar 21
SC 13G
RA CAPITAL MANAGEMENT, L.P.
16 Feb 21
SC 13G
ROCHE FINANCE LTD
16 Feb 21
SC 13G/A
Access Industries Holdings LLC
16 Feb 21
SC 13G
Polaris Partners VIII, L.P.
12 Feb 21
4
Rahul Kakkar
10 Feb 21
4
Edward D. Freedman
10 Feb 21
4
Joanne L. Viney
10 Feb 21
4
Vikas Goyal
10 Feb 21
4
Eric D Larson
10 Feb 21
4
John Sundy
10 Feb 21
4
Katina Dorton
4 Dec 20
3
Katina Dorton
4 Dec 20
4
Daniel J. Becker
23 Nov 20
4
Daniel J. Becker
19 Nov 20
SC 13D
GLAXOSMITHKLINE PLC
3 Aug 20
SC 13G
Versant Venture Capital VI, L.P.
31 Jul 20
SC 13D
Boxer Capital, LLC
30 Jul 20
SC 13G
ORBIMED ADVISORS LLC
28 Jul 20